Eli Lilly Stock Surges 7%, Adding $77 Billion, As Mounjaro Sales Jump 65% And Revenue Outlook Rises
Shares hit a 52-week high after Lilly raised its 2026 sales forecast, though deal charges trimmed its adjusted profit outlook.
Eli Lilly, the drugmaker behind the diabetes and obesity treatments Mounjaro and Zepbound, saw its shares climb 6.67% to $1374.29 in Thursday trading as of 10:49 a.m. ET, adding $77 billion in market value, after it reported third-quarter revenue of $24.4 billion and raised its full-year sales forecast for the third time this year.
A $5.5 billion bump to the forecast
Lilly raised its 2026 revenue forecast to $91 billion to $92 billion, from $85 billion to $87 billion. That is $5.5 billion higher at the midpoint.
Mounjaro sales jumped 65% to $10.72 billion in the third quarter. Zepbound sales reached $5.35 billion, up 49% from a year earlier, CNBC reported.
Foundayo, Lilly's weight-loss pill, generated $184 million in third-quarter sales, short of the roughly $229 million analysts expected, according to CNBC.
Deal charges trim the profit outlook
Lilly now projects 2026 adjusted earnings of $35 to $36 a share, below the prior $35.50 to $36.50. The company said $4.57 a share in deal-related research charges offset a $4.07 underlying increase.
A record run for the stock
The shares touched a new 52-week high of $1374.29 on Thursday and were on pace for their biggest one-day gain since June 26, when they rose 7.1%.
They were already up about 20% year to date at Wednesday's close, against about 13% for the S&P 500. They had been within 2% of their highest close of the past year, set October 22, and were heading for a fourth straight daily gain.
Lilly develops, manufactures and markets human pharmaceuticals as a single business. Its lineup spans diabetes and obesity, cancer, immune and neurological conditions. In the prior reported quarter, it posted revenue of $23 billion, up 47.7% from a year earlier, with net income of $7.1 billion.
Thursday's quarter put Lilly's full-year revenue guidance at $91 billion to $92 billion, with Mounjaro and Zepbound together bringing in more than $16 billion in the third quarter alone.
Sources
- Eli Lilly (LLY) earnings Q3 2026 — CNBC
- Eli Lilly stock jumps as drugmaker raises outlook on booming sales of diabetes and obesity treatments — Yahoo Finance
- Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance | Investor's Business Daily — investors.com
- Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying. — MarketWatch
- Eli Lilly lifts sales outlook as blockbuster weight-loss drugs fuel growth (LLY:NYSE) | Seeking Alpha — seekingalpha.com
- The company's filing (Eli Lilly and Co.) — SEC filing
- The company's announcement (Eli Lilly and Co.) — the company
- Eli Lilly and Co. — Form 10-Q for the quarter ended 2026-06-30 (quarterly results) — SEC EDGAR